👋 Hey, let’s get into it. Moderna delivered positive cancer vaccine data. Wall Street responded like someone had attached the wrong spreadsheet.

Its experimental personalized mRNA therapy, added to Merck’s Keytruda after melanoma surgery, cut the relative risk of recurrence or death by 42% versus Keytruda alone in Phase 3. That’s a meaningful clinical win for an approach tailored to each patient’s tumor.

After results circulated early, Moderna shares plunged nearly 25% intraday on October 22. Analysts pointed to lofty investor expectations. Apparently, “statistically significant” wasn’t significant enough for Wall Street.

🎯 BMS and SystImmune’s Bispecific ADC Doubles Progression-Free Survival
BMS and SystImmune’s iza-bren extended median progression-free survival to 11.1 months versus 5.7 months with chemotherapy in a 422-patient Phase 3 study in China. Patients had EGFR-mutated non-small cell lung cancer that progressed after targeted therapy. The antibody-drug conjugate binds EGFR and HER3 to deliver its cancer-killing payload, adding evidence for a two-target approach after resistance develops. Overall survival remains immature, and two cases of lung inflammation were reported. The result strengthens the development case, with global trials still needed to support broader regulatory ambitions. Still, it’s a big win for the program. Or, as Napoleon Dynamite would put it: “Heck yes!”

💊 Gilead Commits $1.275B Upfront to PepStar’s Oral Inflammation Program
Gilead agreed to acquire worldwide rights to PepStar’s oral IL-23 receptor inhibitor program for $1.275 billion upfront, payable at closing. Lead candidate HCXT-2001 is a macrocyclic peptide in Phase 1, targeting an inflammatory pathway already validated by other medicines. The appeal is bringing that biology into a pill for diseases including inflammatory bowel disease. Gilead also sees potential alongside emvistegrast, the ulcerative colitis candidate we covered Thursday, although combination benefits remain unproven. Closing is expected this quarter. The pill is still early, but the invoice is fully developed.

🧪 EQT Agrees to Take Qiagen Private in a $12.1B Deal
EQT and its co-investors agreed to take Qiagen private at a €10.8 billion ($12.1B) enterprise value, including debt. The €46.50 ($51.97) per-share cash offer has unanimous board backing, with closing expected in mid-2027, subject to regulatory clearance and shareholder acceptance. Private ownership could give management more room for long-term investment, although customers will want to see what that means in practice. For those who have never worked in a lab, Qiagen supplies the sample-preparation kits, molecular tests, and tools that help labs turn biological material into usable answers. They’re also the blue boxes on the top shelf you’ll often see postdocs pointing and cursing at as they redo an experiment.

🍽️ Abbott Plans to Spin Off Its $8.5B Nutrition Business
Abbott plans to separate its Nutrition business into an independent public company by the end of 2027. The unit generates approximately $8.5 billion in annual sales and includes Ensure, Similac, PediaSure, and Glucerna. Abbott would retain its devices, diagnostics, and other healthcare businesses. The logic: nutrition has different customers, manufacturing demands, and growth priorities, and a standalone company could focus investment accordingly. For suppliers and commercial teams, a familiar customer is preparing to become two. For all our protein-obsessed readers out there, this might be the closest thing to a “protein pure play” you’ll find on the public markets.

Put your brand in front of scientists, founders, investors, operators, and other professionals across biotech and pharma.

BioNucleus Briefing has 2,500+ combined subscriptions across our email and LinkedIn newsletters, with one exclusive sponsor per issue.

Think your company could be a fit? Learn more about our audience and get in touch about an upcoming campaign.

Alright, back to the newsletter.

🎯 Genmab’s Rina-S Cuts Death Risk 57% in Ovarian Cancer Trial
Genmab reported 57% lower death risk versus chemotherapy in Phase 3 platinum-resistant ovarian cancer, using Rina-S’s full intention-to-treat population.

🤝 Roche Licenses Zymeworks’ Cancer Trispecific for Up to $718M
Roche licensed Zymeworks’ investigational ZW209 for $55 million upfront and up to $718 million in milestones, adding a trispecific antibody designed to engage a tumor target and two T-cell signals.

🫁 Amgen’s Imdelltra Combo Adds 8.4 Months to Median Survival
Amgen’s Imdelltra plus Imfinzi delivered 21.1 versus 12.7 months’ median survival with Imfinzi alone in Phase 3 extensive stage small-cell lung cancer.

🏭 Pfizer Confirms More Manufacturing Job Cuts
Pfizer confirmed manufacturing workforce reductions in Michigan and North Carolina, extending its restructuring into additional production sites.

🙌 Merck and Kelun ADC Combo Extends Lung Cancer PFS to 15 Months
Merck and Kelun’s sac-TMT plus Keytruda delivered 15 versus 5.7 months’ progression-free survival against chemotherapy plus Keytruda in China’s Phase 3 first-line PD-L1-negative nonsquamous lung cancer trial.

✅ Roche’s Divarasib Beats Existing KRAS Drugs on Survival
Roche’s investigational divarasib delivered 17.7 versus 12 months’ median survival against physician-choice sotorasib or adagrasib in Phase 3 previously treated KRAS G12C-mutated lung cancer.

👁️ Alcon Acquires Neurotech for $550M
Alcon acquired Neurotech for $550 million, adding Encelto, an implanted cell therapy for a rare retinal disease that received FDA approval in March 2025.

🧪 J&J’s Experimental Prostate Cancer Drug Shrinks Tumors in 12 of 16 Patients
J&J’s investigational RIPTAC JNJ-6143 produced confirmed tumor responses in 12 of 16 patients with advanced prostate cancer in a Phase 1 cohort.

If you’re an avid BioNucleus reader, first: we love you. Second: you’ve probably noticed that practically every edition features a major pharma company licensing a drug from China. At this point, BD teams probably have the wire instructions saved under “favorites.” Now the US Treasury wants a closer look at the shopping trip. Specifically, whether anyone’s putting equity in the cart.

On October 22, the Treasury proposed expanding outbound investment controls to biotechnology under the COINS Act. Certain U.S. investments involving covered businesses in countries of concern, including China, could be prohibited or require notification. The scope includes drug compounds, sequencing, biomanufacturing, bioinformatics, and automated scientific discovery.

Before anyone cancels the next partnering meeting, here’s the important distinction: investing in a company and licensing its drug are different transactions. Ordinary licenses involving upfront payments, milestones, and royalties generally fall outside the proposal’s investment definition. Equity stakes, certain convertible debt, joint ventures, and some fund investments fall within its scope.

That leaves room for the licensing model behind so many pharma pipelines. But add ownership, governance rights, or a jointly owned company, and things get complicated. Calling the agreement a “license” won’t settle its treatment. Legal will need more than the filename.

For founders and investors, the consequences could reach beyond pharma’s next drug purchase into venture funding and how partnerships are built. Two deals accessing similar science could face different constraints because the money and ownership flow differently. The cap table now deserves its own diligence meeting.

Public comments close December 7. These are proposed restrictions, with an effective date to come in the final rule. Until then: lovely molecule, sir. Please place your term sheet into the tray for review.

This is how much Lycia expects in gross proceeds from its upsized IPO, priced at $18 per share. Its platform targets disease-causing proteins outside cells for degradation. That’s substantial funding for extracellular cleanup.

Here’s what biotech Redditors are talking about:

🦣 Biotech Reddit Debates Colossal’s Hype and the Theranos Comparison
A recent thread asked whether Colossal’s de-extinction promises warranted a Theranos comparison. Several commenters pushed back: ambitious timelines and real technical work are different from fabricating capabilities. Others questioned the hype, deadlines, and commercial purpose. Sooo…what exactly do we do once we have the woolly mammoth? It’s giving Elon Musk delivery-date energy, except I’m waiting for a pet mammoth instead of a car. Whenever it arrives, please tell me it comes house-trained.

🏝️ What’s the Most Chill Job in Biotech?
One commenter took the question literally: cryo-EM, obviously. Beyond the temperature jokes, replies pointed to stable funding and sensible management. One commenter liked early proof-of-concept R&D’s lighter deadline pressure, despite fewer advancement opportunities. Others described blending into big pharma, doing 20-ish hours of actual work, and spending the rest looking busy. It seems the dream role combines interesting science, a solvent employer, and a calendar that recognizes weekends. Please forward the job posting when you find it.

🤖 Google’s Personal Health AI Gets a Nature Evaluation
A Nature study evaluated Google’s research prototype combining wearable data, medical records, and specialist AI agents to answer health questions and provide personalized guidance.

🦧 Ancient Viral DNA Silences a Gene in Chimpanzees
Researchers linked an ancient viral insertion in chimpanzee DNA to silencing LINC00662, a gene active in humans, with experiments implicating early neural-development programs.

🦘 Australia’s Clinical Trial Pitch Gains Attention
CROs interviewed by BioSpace pointed to Australia’s predictable trial-startup processes and R&D tax incentives as attractions for sponsors navigating uncertainty in the United States.

👖 GLP-1 Weight Loss Brings Business to Tailors and Cobblers
Tailors and cobblers interviewed by Reuters reported more clothing alterations and belt-shortening requests from customers using GLP-1 drugs, an unexpected downstream business opportunity.

🤖 Pathos Raises $237M With BMS and Tempus in Its AI Push
Pathos raised a $237 million Series E led by BMS to expand Foundry, its AI drug-development platform, and advance its oncology pipeline. New collaborations with BMS and Tempus extend the strategy into Alzheimer’s and other neurological conditions, using longitudinal clinical data to inform development decisions. A separate $55 million, five-year Tempus agreement buys data access; that’s spending, rather than additional fundraising. The AI pitch now comes with a pharma partner, a clinical pipeline, and a very real data bill. It was quite a busy week over at Pathos.

🦴 October 27, 2004: Scientists Introduce the “Hobbit” Human
On this day in 2004, scientists publicly introduced Homo floresiensis, a small-bodied ancient human discovered on Indonesia’s Flores island the previous year. The best-known adult stood about 3 feet 6 inches tall, earning the species its “hobbit” nickname and giving the human family tree a branch Tolkien would appreciate. Later research revised the fossils’ age to roughly 100,000–60,000 years old, replacing early claims of much more recent survival.

After that BioBits story about GLP-1 users keeping tailors and cobblers busy, I’m picturing an out-of-touch Silicon Valley VC calling an emergency all-hands:

“Team…are you familiar with a technology called the adjustable belt? Texas company. Incredible traction. 100% leather. It’s our latest post-GLP-1 play. We just invested $500 million at a $20 billion valuation.”

Naturally, they’re calling it a waist-management platform.

That’s all for today. See you Thursday for the next issue.

✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead